Teriparatide + Zoledronic Acid

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Osteoporosis, Post-menopausal

Conditions

Osteoporosis, Post-menopausal

Trial Timeline

Jul 1, 2009 โ†’ Apr 1, 2012

About Teriparatide + Zoledronic Acid

Teriparatide + Zoledronic Acid is a approved stage product being developed by Eli Lilly for Osteoporosis, Post-menopausal. The current trial status is completed. This product is registered under clinical trial identifier NCT00927186. Target conditions include Osteoporosis, Post-menopausal.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT00927186ApprovedCompleted
NCT01153425ApprovedCompleted

Competing Products

20 competing products in Osteoporosis, Post-menopausal

See all competitors